MAGEA3 and metastatic melanoma: that used autologous Dendritic Cell-Derived EVs (DEX) loaded with Melanoma-associated antigen 3 (MAGE-3) as immunotherapy in metastatic melanoma patients showed no major toxicity, a partial response, and tumor regressions at skin and lymph node sites [12].